The Danish laboratory responsible for producing the only authorized vaccine against monkeypox announced this Wednesday (24) an agreement with the WHO (World Health Organization) to facilitate its distribution in Latin America and the Caribbean.
“Vaccine deliveries will start in September”, indicates the Bavarian Nordic laboratory.
The agreement signed with PAHO (Pan American Health Organization, WHO’s regional office for the Americas, seeks to “facilitate equitable access to the company’s vaccine against monkeypox in Latin American and Caribbean countries”, explains the laboratory. in a statement.
Initially limited to western and central Africa, monkeypox has spread since May to other parts of the world, especially Europe and the United States, with a total of 40,000 cases reported by the end of August.
Marketed by Bavarian Nordic under the name Jynneos in North America and Imvanex in Europe, it is a vaccine against smallpox, a deadly disease eradicated in 1980, which is currently used against monkeypox.
The term “monkey pox” was used after the virus was detected in monkeys at a laboratory in Denmark in 1958. However, the virus has also been found in other animals, especially rodents.
The disease was first discovered in a human in the year 1970, and it is less dangerous and contagious than smallpox.
The virus can be transmitted from animals to humans, but the recent explosion in cases is due to human-to-human transmission through close contacts.
Chad-98Weaver, a distinguished author at NewsBulletin247, excels in the craft of article writing. With a keen eye for detail and a penchant for storytelling, Chad delivers informative and engaging content that resonates with readers across various subjects. His contributions are a testament to his dedication and expertise in the field of journalism.
